7 results on '"de Mulder, Maarten"'
Search Results
2. Intensive glucose regulation in hyperglycemic acute coronary syndrome: results of the randomized BIOMarker study to identify the acute risk of a coronary syndrome-2 (BIOMArCS-2) glucose trial.
- Author
-
de Mulder M, Umans VA, Cornel JH, van der Zant FM, Stam F, Oemrawsingh RM, Akkerhuis KM, and Boersma E
- Subjects
- Acute Coronary Syndrome pathology, Acute Coronary Syndrome therapy, Aged, Biomarkers blood, Blood Glucose drug effects, Creatine Kinase blood, Female, Humans, Hyperglycemia complications, Male, Middle Aged, Myocardial Infarction pathology, Myocardial Perfusion Imaging, Myocardium pathology, Prospective Studies, Troponin T blood, Acute Coronary Syndrome complications, Hyperglycemia drug therapy, Hypoglycemic Agents administration & dosage, Insulin administration & dosage, Myocardial Infarction complications
- Abstract
Importance: Elevated plasma glucose levels in patients with acute coronary syndrome (ACS) on hospital admission are associated with increased mortality. Clinical trials of glucose regulation have provided inconsistent results with respect to cardiovascular outcomes, perhaps because target glucose levels have been suboptimal., Objective: To study the effectiveness and safety of intensive glucose management in patients with ACS who have hyperglycemia, aiming at strict blood glucose normalization., Design, Setting, and Participants: Single-center, prospective, open-label, randomized clinical trial in a large teaching hospital. Patients with ACS with an admission plasma glucose level of 140 to 288 mg/dL were eligible for inclusion and enrolled from July 23, 2008, to February 8, 2012. Patients with insulin-dependent diabetes mellitus were excluded. Informed consent was obtained from 294 patients, who were randomized. Of these, 93.6% received percutaneous coronary intervention (PCI)., Interventions: Intensive glucose management strategy, aiming at a plasma glucose level of 85 to 110 mg/dL by using intravenous insulin, or to conventional expectative glucose management., Main Outcomes and Measures: End points were assessed according to the intention-to-treat principle. The primary end point was high-sensitivity troponin T value 72 hours after admission (hsTropT72); secondary end points, area under the curve of creatine kinase, myocardial band (AUC-CK-MB), release and myocardial perfusion scintigraphy findings at 6 weeks' follow-up., Results: In the intensive management arm, median hsTropT72 was 1197 ng/L (25th and 75th percentiles of distribution, 541-2296 ng/L) vs 1354 ng/L (530-3057 ng/L) in the conventional arm (P = .41). Median AUC-CK-MB was 2372 U/L (1242-5004 U/L) vs 3171 U/L (1620-5337 U/L) (P = .18). The difference in median extent of myocardial injury measured by myocardial perfusion scintigraphy was not significant (2% vs 4%) (P = .07). Severe hypoglycemia (<50 mg/dL) was rare and occurred in 13 patients. Before discharge, death or a spontaneous second myocardial infarction occurred in 8 patients (5.7%) vs 1 (0.7%) (P = .04). CONCLUSIONS AND RELEVANCE Intensive glucose regulation did not reduce infarct size in hyperglycemic patients with ACS treated with PCI, and was associated with harm. Future studies should focus on patients with ACS who have persistently elevated blood glucose after PCI, and should evaluate alternative strategies for optimizing glycemia., Trial Registration: www.trialregister.nl Identifier: NTR1205.
- Published
- 2013
- Full Text
- View/download PDF
3. EuroHeart score for the evaluation of in-hospital mortality in patients undergoing percutaneous coronary intervention.
- Author
-
de Mulder M, Gitt A, van Domburg R, Hochadel M, Seabra-Gomes R, Serruys PW, Silber S, Weidinger F, Wijns W, Zeymer U, Hamm C, and Boersma E
- Subjects
- Aged, Europe, Female, Hospital Mortality, Humans, Male, Middle Aged, Myocardial Infarction mortality, Risk Assessment, Angioplasty, Balloon, Coronary mortality, Myocardial Infarction therapy, Severity of Illness Index
- Abstract
Aims: The applicability of currently available risk prediction models for patients undergoing percutaneous coronary interventions (PCIs) is limited. We aimed to develop a model for the prediction of in-hospital mortality after PCI that is based on contemporary and representative data from a European perspective., Methods and Results: Our analyses are based on the Euro Heart Survey of PCIs, which contains information on 46 064 consecutive patients who underwent PCI for different indications in 176 participating European centres during 2005-08. Patients were randomly divided into a training (n = 23 032) and a validation (n = 23 032) set with similar characteristics. In these sets, 339 (1.5%) and 305 (1.3%) patients died during hospitalization, respectively. On the basis of the training set, a logistic model was constructed that related 16 independent patient or lesion characteristics with mortality, including PCI indication, advanced age, haemodynamic instability, multivessel disease, and proximal LAD disease. In both the training and validation data sets, the model had a good performance in terms of discrimination (C-index 0.91 and 0.90, respectively) and calibration (Hosmer-Lemeshow P-value 0.39 and 0.18, respectively)., Conclusion: In-hospital mortality in PCI patients was well predicted by a risk score that contains 16 factors. The score has strong applicability for European practices.
- Published
- 2011
- Full Text
- View/download PDF
4. Admission glucose does not improve GRACE score at 6 months and 5 years after myocardial infarction.
- Author
-
de Mulder M, van der Ploeg T, de Waard GA, Boersma E, and Umans VA
- Subjects
- Aged, Biomarkers metabolism, Female, Follow-Up Studies, Hospitalization, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Prognosis, ROC Curve, Risk Assessment methods, Blood Glucose metabolism, Myocardial Infarction blood, Myocardial Infarction mortality
- Abstract
Objective: Admission plasma glucose (APG) is a biomarker that predicts mortality in myocardial infarction (MI) patients. Therefore, APG may improve risk stratification based on the GRACE risk score., Methods: We collected data on baseline characteristics and long-term (median 55 months) outcome of 550 MI patients who entered our hospital in 2003 and 2006. We determined the GRACE risk score at admission for each patient, which was entered in a logistic regression model, together with APG, to evaluate their prognostic value for 6-month and 5-year mortality., Results: Patients with APG ≥7.8 mmol/l had a higher mortality than those with APG levels <7.8 mmol/l; 6 months: 13.7 versus 3.6%, p value <0.001; 5 years: 20.4 versus 11.1%, p value 0.003. After adjustment for the GRACE risk score variables, APG appeared a significant predictor of 6-month and 5-year mortality, adjusted OR 1.17 (1.06-1.29) and 1.12 (1.03-1.22). The combination of the GRACE risk score and APG increased the model's performance (discrimination C-index 0.87 vs. 0.85), although the difference was not significant (p = 0.095). Combining the GRACE risk score and APG reclassified 12.9% of the patients, but the net reclassification improvement was nonsignificant (p = 0.146)., Conclusion: APG is a predictor of 6-month and 5-year mortality, each mmol/l increase in APG being associated with a mortality increase of 17 and 12%, respectively, independent of the GRACE risk score. However, adding APG to the GRACE model did not result in significantly improved clinical risk stratification., (Copyright © 2012 S. Karger AG, Basel.)
- Published
- 2011
- Full Text
- View/download PDF
5. Elevated admission glucose is associated with increased long-term mortality in myocardial infarction patients, irrespective of the initially applied reperfusion strategy.
- Author
-
de Mulder M, Cornel JH, van der Ploeg T, Boersma E, and Umans VA
- Subjects
- Aged, Angioplasty, Balloon, Coronary, Coronary Angiography, Diabetic Angiopathies blood, Diabetic Angiopathies mortality, Diabetic Angiopathies therapy, Female, Humans, Hyperglycemia epidemiology, Hyperglycemia physiopathology, Kaplan-Meier Estimate, Male, Middle Aged, Multivariate Analysis, Prognosis, Risk Assessment, Survival Analysis, Blood Glucose analysis, Myocardial Infarction blood, Myocardial Infarction mortality, Myocardial Reperfusion
- Abstract
Background: It is uncertain if elevated admission plasma glucose (APG) remains an independent determinant of longer-term mortality in myocardial infarction (MI) patients with early restoration of coronary reperfusion by primary percutaneous coronary intervention. The objective of the study was to describe the relation between elevated APG and long-term mortality in MI patients undergoing invasive management., Methods: We studied 1,185 consecutive MI patients treated in the Medical Center Alkmaar in the separate years 1996 and 1999 (preinvasive era) and 2003 and 2006 (invasive era). In both eras, APG was derived according to a standard protocol. A multivariate Cox regression model was created to study the relation between APG, reperfusion era, and 5-year mortality., Results: During a median follow-up of 63 months, 261 patients had died. Mortality was lower in the invasive (19%) than in the preinvasive era (28%). Increased APG was associated with increased mortality, irrespective of the initial reperfusion strategy, although the relation was more pronounced in the preinvasive era (P value for heterogeneity of effects < .001). Each millimole-per-liter APG increase corresponded to a 7% increased mortality (adjusted hazard ratio 1.07, 95% CI 1.04-1.10). Patients with an APG >11 mmol/L had nearly 2-fold higher mortality (hazard ratio 1.9, 95% CI 1.3-2.7) than those with lower values., Conclusion: Elevated APG remains a determinant of long-term mortality in MI patients, irrespective of the advances that have been made in reperfusion therapy., (2010 Mosby, Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
6. Infarct size in primary angioplasty without on-site cardiac surgical backup versus transferal to a tertiary center: a single photon emission computed tomography study.
- Author
-
Knaapen P, de Mulder M, van der Zant FM, Peels HO, Twisk JW, van Rossum AC, Cornel JH, and Umans VA
- Subjects
- Female, Hospitals, Community, Humans, Male, Middle Aged, Myocardial Infarction diagnostic imaging, Myocardial Infarction enzymology, Myocardial Reperfusion Injury diagnostic imaging, Technetium Tc 99m Sestamibi, Time Factors, Tomography, Emission-Computed, Single-Photon, Angioplasty, Balloon, Myocardial Infarction pathology, Myocardial Infarction therapy, Patient Transfer
- Abstract
Background: Primary percutaneous coronary intervention (PCI) performed in large community hospitals without cardiac surgery back-up facilities (off-site) reduces door-to-balloon time compared with emergency transferal to tertiary interventional centers (on-site). The present study was performed to explore whether off-site PCI for acute myocardial infarction results in reduced infarct size., Methods and Results: One hundred twenty-eight patients with acute ST-segment elevation myocardial infarction were randomly assigned to undergo primary PCI at the off-site center (n = 68) or to transferal to an on-site center (n = 60). Three days after PCI, (99m)Tc-sestamibi SPECT was performed to estimate infarct size. Off-site PCI significantly reduced door-to-balloon time compared with on-site PCI (94 +/- 54 versus 125 +/- 59 min, respectively, p < 0.01), although symptoms-to-treatment time was only insignificantly reduced (257 +/- 211 versus 286 +/- 146 min, respectively, p = 0.39). Infarct size was comparable between treatment centers (16 +/- 15 versus 14 +/- 12%, respectively p = 0.35). Multivariate analysis revealed that TIMI 0/1 flow grade at initial coronary angiography (OR 3.125, 95% CI 1.17-8.33, p = 0.023), anterior wall localization of the myocardial infarction (OR 3.44, 95% CI 1.38-8.55, p < 0.01), and development of pathological Q-waves (OR 5.07, 95% CI 2.10-12.25, p < 0.01) were independent predictors of an infarct size > 12%., Conclusions: Off-site PCI reduces door-to-balloon time compared with transferal to a remote on-site interventional center but does not reduce infarct size. Instead, pre-PCI TIMI 0/1 flow, anterior wall infarct localization, and development of Q-waves are more important predictors of infarct size.
- Published
- 2009
- Full Text
- View/download PDF
7. Long-Term Follow-Up of the Randomized (BIOMArCS-2) Glucose Trial: Intensive Glucose Regulation in Hyperglycemic Acute Coronary Syndrome.
- Author
-
van den Berg, Victor J., Umans, Victor A. W. M., Stam, Frank, de Mulder, Maarten, Akkerhuis, K. Martijn, Cornel, Jan H., Kardys, Isabella, and Boersma, Eric
- Subjects
- *
RANDOMIZED controlled trials , *MYOCARDIAL infarction , *BLOOD sugar monitoring , *MORTALITY , *MEDICAL research - Abstract
The article focuses on a randomized trial BIOMArCS-2 Glucose which was conducted to evaluate the effect of using intensive glucose control (IGC) in myocardial infarction (MI). Topics discussed include no association between use of IGC in hyperglycemic MI patients and improved outcomes, lowering blood glucose in hyperglycemic causes excess mortality and risk of higher mortality during long term follow-up.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.